Royalty Pharma Management

Management criteria checks 3/4

Royalty Pharma's CEO is Pablo Legorreta, appointed in Jan 1996, has a tenure of 28.25 years. directly owns 0.82% of the company’s shares, worth $138.45M. The average tenure of the management team and the board of directors is 2.3 years and 3.8 years respectively.

Key information

Pablo Legorreta

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure28.3yrs
CEO ownership0.8%
Management average tenure2.3yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Apr 04
Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22
Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26
Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Royalty Pharma: Unique Diversification, Bear Market Performer

May 26

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25
The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma Offers A Unique Long-Term Investment Opportunity

Mar 01

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Jan 25
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Jan 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Royalty Pharma: A Pharma-Like Company Without The Same Risks

Dec 27

CEO Compensation Analysis

How has Pablo Legorreta's remuneration changed compared to Royalty Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

US$1b

Sep 30 2023n/an/a

US$184m

Jun 30 2023n/an/a

US$255m

Mar 31 2023n/an/a

US$332m

Dec 31 2022n/an/a

US$43m

Sep 30 2022n/an/a

US$507m

Jun 30 2022n/an/a

US$466m

Mar 31 2022n/an/a

US$602m

Dec 31 2021US$50mUS$8m

US$620m

Sep 30 2021n/an/a

US$783m

Jun 30 2021n/an/a

US$972m

Mar 31 2021n/an/a

US$493m

Dec 31 2020US$56mn/a

US$495m

Sep 30 2020n/an/a

US$2b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$29mn/a

US$2b

Compensation vs Market: Insufficient data to establish whether Pablo's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Pablo's compensation has been consistent with company performance over the past year.


CEO

Pablo Legorreta (58 yo)

28.3yrs

Tenure

Mr. Pablo Gerardo Legorreta serves as Chairman of the Board at ProKidney Corp. He serves as the Chief Executive Officer and Co-Founder at RP Management, LLC. He also serves as Chairman of the Board at Roya...


Leadership Team

NamePositionTenureCompensationOwnership
Pablo Legorreta
Founder28.3yrsno data0.82%
$ 138.4m
Terrance Coyne
Executive VP & CFOno dataUS$4.35m0.19%
$ 31.7m
George Lloyd
Executive VP of Investments & Chief Legal Officer1.5yrsUS$4.35m0.24%
$ 40.6m
Christopher Hite
Vice Chairman & Executive VP4yrsUS$4.35m0.016%
$ 2.6m
Marshall Urist
Executive VP and Head of Research & Investments3.3yrsUS$4.35m0.015%
$ 2.5m
Arthur McGivern
Executive Vice President of Investments & General Counsel1.5yrsno datano data
Ashwin Pai
Executive Vice President of Investmentsless than a yearno datano data
Kristin Stafford
Senior VP & Chief Accounting Officerno datano datano data
Eric Schneider
Senior VP & Chief Technology Officerless than a yearno datano data
James Reddoch
Executive VP of Investments & Chief Scientific Officer3.3yrsUS$3.40m0.19%
$ 31.9m
George Grofik
Senior VP and Head of Investor Relations & Communicationsno datano datano data
Alessandra Sassun
Senior VP & Head of Human Capital2.3yrsno datano data

2.3yrs

Average Tenure

56yo

Average Age

Experienced Management: RPRX's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Pablo Legorreta
Founder28.3yrsno data0.82%
$ 138.4m
David Hodgson
Independent Director1.8yrsUS$452.45k0.0019%
$ 327.1k
Rory Riggs
Director3.8yrsno data0.073%
$ 12.4m
Ted Love
Independent Director3.8yrsUS$423.37k0.0065%
$ 1.1m
Errol De Souza
Independent Director3.8yrsUS$423.37k0.013%
$ 2.1m
Henry Fernandez
Lead Independent Director3.8yrsUS$423.37k0.021%
$ 3.5m
Gregory Norden
Independent Director3.8yrsUS$423.37k0.013%
$ 2.1m
Bonnie Bassler
Independent Director3.8yrsUS$423.37k0.0090%
$ 1.5m
Mario Giuliani
Director3.8yrsno data12.08%
$ 2.0b
Catherine Engelbert
Independent Director3.8yrsUS$423.37k0.0057%
$ 961.0k

3.8yrs

Average Tenure

64.5yo

Average Age

Experienced Board: RPRX's board of directors are considered experienced (3.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.